310 related articles for article (PubMed ID: 21793095)
1. High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma.
Wang X; Asmann YW; Erickson-Johnson MR; Oliveira JL; Zhang H; Moura RD; Lazar AJ; Lev D; Bill K; Lloyd RV; Yaszemski MJ; Maran A; Oliveira AM
Genes Chromosomes Cancer; 2011 Nov; 50(11):849-58. PubMed ID: 21793095
[TBL] [Abstract][Full Text] [Related]
2. Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.
Zhang K; Chu K; Wu X; Gao H; Wang J; Yuan YC; Loera S; Ho K; Wang Y; Chow W; Un F; Chu P; Yen Y
Cancer Res; 2013 Feb; 73(4):1298-307. PubMed ID: 23393200
[TBL] [Abstract][Full Text] [Related]
3. Amplification of FRS2 in atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma: a clinicopathological and genetic study of 146 cases.
Jing W; Lan T; Chen H; Zhang Z; Chen M; Peng R; He X; Zhang H
Histopathology; 2018 Jun; 72(7):1145-1155. PubMed ID: 29368794
[TBL] [Abstract][Full Text] [Related]
4. Expression of FRS2 in atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: an immunohistochemical analysis of 182 cases with genetic data.
Jing W; Lan T; Qiu Y; Peng R; Lu Y; Chen H; Chen M; He X; Chen C; Zhang H
Diagn Pathol; 2021 Oct; 16(1):96. PubMed ID: 34696768
[TBL] [Abstract][Full Text] [Related]
5. Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis.
He X; Pang Z; Zhang X; Lan T; Chen H; Chen M; Yang H; Huang J; Chen Y; Zhang Z; Jing W; Peng R; Zhang H
Am J Surg Pathol; 2018 Sep; 42(9):1143-1155. PubMed ID: 30001240
[TBL] [Abstract][Full Text] [Related]
6. High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma.
Lee SE; Kim YJ; Kwon MJ; Choi DI; Lee J; Cho J; Seo SW; Kim SJ; Shin YK; Choi YL
Histol Histopathol; 2014 Jan; 29(1):127-38. PubMed ID: 23852861
[TBL] [Abstract][Full Text] [Related]
7. Clinical Application of Chromosome Microarray Analysis in the Diagnosis of Lipomatous Tumors.
Pei J; Flieder DB; Talarchek JN; Cooper HS; Patchefsky AS; Wei S
Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):592-598. PubMed ID: 33734108
[TBL] [Abstract][Full Text] [Related]
8. Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma.
Erickson-Johnson MR; Seys AR; Roth CW; King AA; Hulshizer RL; Wang X; Asmann YW; Lloyd RV; Jacob EK; Oliveira AM
Mod Pathol; 2009 Dec; 22(12):1541-7. PubMed ID: 19820690
[TBL] [Abstract][Full Text] [Related]
9. The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers.
Shimada S; Ishizawa T; Ishizawa K; Matsumura T; Hasegawa T; Hirose T
Hum Pathol; 2006 Sep; 37(9):1123-9. PubMed ID: 16938516
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization.
Tap WD; Eilber FC; Ginther C; Dry SM; Reese N; Barzan-Smith K; Chen HW; Wu H; Eilber FR; Slamon DJ; Anderson L
Genes Chromosomes Cancer; 2011 Feb; 50(2):95-112. PubMed ID: 21117066
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis.
Creytens D; Van Gorp J; Speel EJ; Ferdinande L
Anticancer Res; 2015 Apr; 35(4):1835-42. PubMed ID: 25862836
[TBL] [Abstract][Full Text] [Related]
12. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.
Italiano A; Bianchini L; Keslair F; Bonnafous S; Cardot-Leccia N; Coindre JM; Dumollard JM; Hofman P; Leroux A; Mainguené C; Peyrottes I; Ranchere-Vince D; Terrier P; Tran A; Gual P; Pedeutour F
Int J Cancer; 2008 May; 122(10):2233-41. PubMed ID: 18214854
[TBL] [Abstract][Full Text] [Related]
13. High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: A cytogenomic microarray analysis of 47 cases.
Ricciotti RW; Baraff AJ; Jour G; Kyriss M; Wu Y; Liu Y; Li SC; Hoch B; Liu YJ
Cancer Genet; 2017 Dec; 218-219():69-80. PubMed ID: 29153098
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the 12q amplicons by high-resolution, oligonucleotide array CGH and expression analyses of a novel liposarcoma cell line.
Persson F; Olofsson A; Sjögren H; Chebbo N; Nilsson B; Stenman G; Aman P
Cancer Lett; 2008 Feb; 260(1-2):37-47. PubMed ID: 18160213
[TBL] [Abstract][Full Text] [Related]
15. Utility of fluorescence in situ hybridization to detect MDM2 amplification in liposarcomas and their morphological mimics.
Kimura H; Dobashi Y; Nojima T; Nakamura H; Yamamoto N; Tsuchiya H; Ikeda H; Sawada-Kitamura S; Oyama T; Ooi A
Int J Clin Exp Pathol; 2013; 6(7):1306-16. PubMed ID: 23826411
[TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma.
Crago AM; Singer S
Curr Opin Oncol; 2011 Jul; 23(4):373-8. PubMed ID: 21552124
[TBL] [Abstract][Full Text] [Related]
17. Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component.
Adachi T; Oda Y; Sakamoto A; Saito T; Tamiya S; Masuda K; Tsuneyoshi M
Int J Surg Pathol; 2001 Apr; 9(2):99-109. PubMed ID: 11484509
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.
Hanes R; Grad I; Lorenz S; Stratford EW; Munthe E; Reddy CC; Meza-Zepeda LA; Myklebost O
Oncotarget; 2016 Aug; 7(34):54583-54595. PubMed ID: 27409346
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical, cytogenetic, and molecular cytogenetic characterization of both components of a dedifferentiated liposarcoma: implications for histogenesis.
Nishio J; Iwasaki H; Nabeshima K; Naito M
Anticancer Res; 2015 Jan; 35(1):345-50. PubMed ID: 25550570
[TBL] [Abstract][Full Text] [Related]
20. MDM2 copy numbers in well-differentiated and dedifferentiated liposarcoma: characterizing progression to high-grade tumors.
Ware PL; Snow AN; Gvalani M; Pettenati MJ; Qasem SA
Am J Clin Pathol; 2014 Mar; 141(3):334-41. PubMed ID: 24515760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
